Renee Fonseca

Renee Fonseca

Auto-generated profile, based on publicly available information

Renee Fonseca

Department of Human Genetics, University of Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
KMKamira Maharaj
Kamira Maharaj
JPJohn J. Powers
John J. Powers
AAAlex Achille
Alex Achille
MMMelanie Mediavilla-Varela
Melanie Mediavilla-Varela
WGWael Gamal
Wael Gamal
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). However, a high incidence of adverse events has led to frequent discontinuations, limiting the clinical development of these inhibitors. By contrast, the dual PI3Kδ/casein kinase-1-ε (CK1ε) inhibitor umbralisib (TGR-1202) also shows high rates of response in clinical trials but has an improved safety profile with fewer severe adverse events. Toxicities typical of this class of PI3K inhibitors are largely thought to be immune mediated, but they are poorly characterized. Here, we report the effects of idelalisib, duvelisib, and umbralisib on regulatory T cells (Tregs) on normal human T cells, T cells from CLL patients, and T cells in an Eμ-TCL1 adoptive transfer mouse CLL model. Ex vivo studies revealed differential effects of these PI3K inhibitors; only umbralisib treatment sustained normal and CLL-associated FoxP3+ human Tregs. Further, although all 3 inhibitors exhibit antitumor efficacy in the Eμ-TCL1 CLL model, idelalisib- or duvelisib-treated mice displayed increased immune-mediated toxicities, impaired function, and reduced numbers of Tregs, whereas Treg number and function were preserved in umbralisib-treated CLL-bearing mice. Finally, our studies demonstrate that inhibition of CK1ε can improve CLL Treg number and function. Interestingly, CK1ε inhibition mitigated impairment of CLL Tregs by PI3K inhibitors in combination treatment. These results suggest that the improved safety profile of umbralisib is due to its role as a dual PI3Kδ/CK1ε inhibitor that preserves Treg number and function.

13 November 2018 in Blood Advances
Verified
Journal Article
Closed access
KMKamira Maharaj
Kamira Maharaj
JPJohn J. Powers
John J. Powers
AAAlex Achille
Alex Achille
SDSusan Deng
Susan Deng
RFRenee Fonseca
Renee Fonseca
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered roles for epigenetic modification in the regulation of mechanisms contributing to malignant progression of CLL B cells. However, the extent to which epigenetic modifiers can be targeted for therapeutic benefit in CLL patients remains poorly explored. We report for the first time that expression of epigenetic modifier histone deacetylase 6 (HDAC6) is upregulated in CLL patient samples, cell lines, and euTCL1 transgenic mouse models compared with HDAC6 in normal controls. Genetic silencing of HDAC6 conferred survival benefit in euTCL1 mice. Administration of isoform-specific HDAC6 inhibitor ACY738 in the euTCL1 aging and adoptive transfer models deterred proliferation of CLL B cells, delayed disease onset via disruption of B-cell receptor signaling, and sensitized CLL B cells to apoptosis. Furthermore, coadministration of ACY738 and ibrutinib displayed synergistic cell kill against CLL cell lines and improved overall survival compared with either single agent in vivo. These results demonstrate for the first time the therapeutic efficacy of selective HDAC6 inhibition in preclinical CLL models and suggest a rationale for the clinical development of HDAC6 inhibitors for CLL treatment, either alone or in combination with Bruton tyrosine kinase inhibition.

19 July 2019 in F1000Research
Verified
Journal Article
Open access
GFGloria C. Ferreira
Gloria C. Ferreira
JOJenna Oberstaller
Jenna Oberstaller
RFRenée Fonseca
Renée Fonseca
TKThomas E. Keller
Thomas E. Keller
SASwamy Rakesh Adapa
Swamy Rakesh Adapa
RJRays Jiang
Rays Jiang
Background: Basic and clinical scientific research at the University of South Florida (USF) have intersected to support a multi-faceted approach around a common focus on rare iron-related diseases. We proposed a modified version of the National Center for Biotechnology Information’s (NCBI) Hackathon-model to take full advantage of local expertise in building “Iron Hack”, a rare disease-focused hackathon. As the collaborative, problem-solving nature of hackathons tends to attract participants of highly-diverse backgrounds, organizers facilitated a symposium on rare iron-related diseases, specifically porphyrias and Friedreich’s ataxia, pitched at general audiences. Methods: The hackathon was structured to begin each day with presentations by expert clinicians, genetic counselors, researchers focused on molecular and cellular biology, public health/global health, genetics/genomics, computational biology, bioinformatics, biomolecular science, bioengineering, and computer science, as well as guest speakers from the American Porphyria Foundation (APF) and Friedreich’s Ataxia Research Alliance (FARA) to inform participants as to the human impact of these diseases. Results: As a result of this hackathon, we developed resources that are relevant not only to these specific disease-models, but also to other rare diseases and general bioinformatics problems. Within two and a half days, “Iron Hack” participants successfully built collaborative projects to visualize data, build databases, improve rare disease diagnosis, and study rare-disease inheritance. Conclusions: The purpose of this manuscript is to demonstrate the utility of a hackathon model to generate prototypes of generalizable tools for a given disease and train clinicians and data scientists to interact more effectively.

1 December 2015 in Journal of Microbiology & Biology Education
Verified
Journal Article
Open access
Veronica SegarraVeronica Segarra
Veronica Segarra
ADAlexandra A. DeLucia
Alexandra A. DeLucia
RFRenee Fonseca
Renee Fonseca
MPMichael P. Penfold
Michael P. Penfold
KSKatlyn M. Sawyer
Katlyn M. Sawyer
MHMeredith Hein
Meredith Hein
Service learning is a community engagement pedagogy often used in the context of the undergraduate classroom to synergize course-learning objectives with community needs. We find that an effective way to catalyze student engagement in service learning is for student participation to occur outside the context of a graded course, driven by students’ own interests and initiative. In this paper, we describe the creation and implementation of a self-driven service learning program and discuss its benefits from the community, student, and faculty points of view. This experience allows students to explore careers in the sciences as well as identify skill strengths and weaknesses in an environment where mentoring is available but where student initiative and self-motivation are the driving forces behind the project’s success. Self-driven service learning introduces young scientists to the idea that their careers serve a larger community that benefits not only from their discoveries but also from effective communication about how these discoveries are relevant to everyday life.

2 December 2016 in Blood
Verified
Journal Article
Open access
KMKamira Karen Maharaj
Kamira Karen Maharaj
JPJohn J. Powers
John J. Powers
MPMibel Pabon-Saldana
Mibel Pabon-Saldana
RFRenee Fonseca
Renee Fonseca
AAAlex Achille
Alex Achille
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
INTRODUCTION: In the microenvironment of CLL, T cells are characteristically dysfunctional compared to a normal, healthy setting. Idelalisib, an approved PI3Kδ inhibitor has shown successful clinical response in relapsed/refractory CLL, but is associated with a high rate of discontinuation because of likely immune-related severe adverse events (SAE). More recently, increased toxicity has been reported in treatment-naïve patient trials. The described hepatotoxicity, colitis, and pneumonitis appear to be associated with changes in the T cell compartment and specifically regulatory T cells (Tregs). In the phase I trials of the next generation PI3Kδ inhibitor, TGR-1202, a comparable rate of clinical responses have been reported with apparently less toxicity than prior PI3Kδ inhibitors, even with long term follow-up (Burris et al, ASCO 2016). We previously demonstrated in vitrothat TGR-1202 relatively preserved the number and function of normal human T cell subsets, including Tregs, when compared to the other clinically available PI3Kδ inhibitors (Maharaj et al AACR 2016) Herein, we aimed to further investigate how TGR-1202 regulates T cell subsets in a preclinical murine model of CLL. METHODS: For the preclinical model of CLL, we adoptively transferred 25x10^6 leukemic euTCL1 splenocytes into wildtype mice. Following establishment of disease, we orally administered TGR-1202 or duvelisib (PI3Kδγ inhibitor) and quantified immune changes over time using flow cytometry to detect T cell subsets and associated functional markers. Duvelisb was chosen as a comparator since idelalisib is not suitable for murine models, and duvelisib has been shown to have similar efficacy and toxicity as idelalisib in preclinical and clinical studies. RESULTS: First, we confirmed general immune changes typical of CLL progression. Peripheral white blood cell (WBC) count was significantly higher in leukemic mice compared to wildtype (p=0.02). Following oral TGR-1202 or duvelisib treatment, WBC count decreased significantly over time (p<0.001 respectively), suggesting comparable efficacy in disease eradication. Both inhibitors also significantly reduced overall circulating CD3+ T cell number, however TGR-1202 differentially regulated T cell subset ratios previously reported to regulate autoimmunity. These effects were more pronounced in the CLL setting than wildtype. While Tcon:Teff (CD4:CD8) ratio remained intact, Th1:Th2 ratio was increased. Total Treg number was significantly decreased following treatment, leading to increased Tcon:Treg and Teff:Treg ratios. On the Treg population, TGR-1202 maintained expression of functional markers PD-1 and CTLA-4 closer to control when compared to duvelisib (TGR-1202 vs. control PD-1: p=ns, CTLA-4: p=ns ; duvelisib vs. control PD-1: p=0.02* CTLA-4: p=0.03*). This indicated greater retention of Treg suppressive capacity in vivo inTGR-1202 group. Interestingly, overall Th17 number was reduced in both treatments over time but there was greater disruption of Treg:Th17 ratio in duvelisib group (duvelisib vs. control Treg/Th17 p=0.04* ; TGR-1202 vs. control Treg/Th17 p=ns ). In perspective, maintenance of this balance has been extensively reported to mediate autoimmunity. In order to determine susceptibility to apoptosis, we quantified CD95 (FASL) expression. Lower CD95 mean fluorescence intensity (MFI) was observed on CD4, CD8 and Treg populations in both periphery and spleen of TGR-1202 group compared to those treated with duvelisib. Pathology studies are ongoing to assess the toxicity after TGR-1202 or duvelisib treatment in these mice. CONCLUSIONS: In conclusion, we have demonstrated the efficacy of two PI3Kδinhibitors in a murine CLL model and their differential impact on Treg and Th17 compartments, which may be of relevance to study the toxicity in this class of drugs. Extensive studies of the immune modulating effects of TGR-1202 are particularly of interest given its current clinical development and considering the lower rate of SAE observed in trials.

21 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MCManuela Costantino
Manuela Costantino
RFRenée Fonseca
Renée Fonseca
ZLZhengtong Liu
Zhengtong Liu
ZHZhenhong Huang
Zhenhong Huang
SSSriram Sankararaman
Sriram Sankararaman
ADAndy Dahl
Andy Dahl
The importance of gene-environment interactions (G×E) for complex human traits is heavily debated. Recently, biobank-based GWAS have revealed many statistically significant G×E signals, though most lack clear evidence of biological significance. Here, we partly explain this discrepancy by showing that many G×E signals simplify to additive effects on a different phenotype scale, a classical concern that is currently underappreciated. Our results clearly distinguish G×Sex effects on height, which vanish on the log scale, from G×Sex effects on testosterone, where the log scale uncovers biologically meaningful female-specific effects. Across 32 phenotypes in UK Biobank, we find that scaling by a power transformation can explain 46% of PGS×Sex interactions, and that simple log transformation can explain 23%, with similar results for other environments. We also show that phenotype scale can substantially impact GWAS discovery and the construction and evaluation of polygenic scores. Finally, we provide a set of guidelines to consider and choose phenotype scale in modern genetic studies.